{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017049","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-05-14T20:09:02+00:00","discovered_at":"2026-05-14T20:11:00.325340+00:00","generated_at":"2026-05-14T20:57:54.576343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M","bullets":["Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.","Product sales $10.4M, up 28.4% YoY; gross margin 45.0% vs 41.6%.","Cash position $6.8M at Mar 31, 2026, up from $3.8M; generated $3.4M free cash flow in Q1.","Settled all disputes with former contract manufacturer for net $2M payment to ImmuCell, to fund capacity expansion.","Manufacturing output increased to >450K units/month from ~380K in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017049","json":"https://secwatch.observer/filing/0001437749-26-017049.json","markdown":"https://secwatch.observer/filing/0001437749-26-017049.md","text":"https://secwatch.observer/filing/0001437749-26-017049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/0001437749-26-017049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/iccc20260512_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:57:54.576343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40aa1fa7f634d2d26a18d714d5638775822b6494","claim":"IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue approximately $10.4 million, net income $1.9 million, EPS $0.21 per basic share.","evidence_excerpt":"million compared to the first quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects higher volumes, manufacturing efficiencies, and price realization. ImmuCell generated $3.4 million free cash flow in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/0001437749-26-017049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"approximately $10.4 million"},{"label":"Net income","value":"$1.9 million"},{"label":"EPS","value":"$0.21 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}